

# Elective laparoscopic cholecystectomy in a severe hemophilia A patient with inhibitors to factor VII

Santos, Alexandra\*; Antunes, Margarida\*; Diniz, M João\*, Pimentel, Teresa

Hemophilia Centre, Hospital São José, Lisbon – Portugal

## PATIENT PRESENTATION

- 38 years-old severe hemophilia A patient with genetic profile showing a stop mutation
- Inhibitors since he was 14, high titre
- HCV infection detected when he was 25 and treated with peginterferon  $\alpha 2a$  and ribavirin
- Treated on demand for bleeding episodes with either FEIBA® or Novoseven® since 1998, with similar clinical results
- Target-joint: right knee, with severe arthropathy

## LAPAROSCOPIC PROTOCOL

- A laparoscopic cholecystectomy was performed without technical complications (Fig 1)
- The hemostasis of the liver bed was done with Tissuecel®
- Surgical bleeding was considered normal
- Post-operative period without clinical problems.

## PRE-OPERATORY CLINICAL COURSE

- In the previous months he had recurrent episodes of acute lithiasic cholecystitis successfully managed with admission to hospital for conservative therapy
- Abdominal ultrasound revealed a persistent thickened gallbladder
- Proposed for laparoscopic surgery after pluridisciplinary and patient consensus
- A treatment protocol was scheduled using a bypassing agent - the activated recombinant factor VII Novoseven® (rFVIIa) - and acid  $\epsilon$ -aminocaproic (EACA) as adjunctive hemostatic agent.




Fig 1

rFVIIa PROTOCOL		Pre & intra-op.	Pos-op. & D+1	D+2	D+3	D+4	D+5	D+6	D+7
rFVIIa (bolus $\mu g/Kg$ )	110	1	-	-	-	-	-	-	-
	92	-	q2h	q3h	-	-	-	-	-
	60	-	-	-	q3h	q4h	q4h	q6h	q12h
		EACA (bolus)	5g 6/6h				3g 8/8h		

Total rFVIIa dose administrated:  
287.6 mg

## FINAL CONSIDERATIONS

- Elective surgery in hemophilia patients with inhibitors is a major undertaking, owing to the bleeding complications.
- rFVIIa proved to be efficacious in the initiation and maintenance of hemostasis during and after this elective surgery.
- The inhibitor titre had no anamnestic response.
- No adverse events were observed related to rFVIIa administration.
- The economic impact of this procedure was obviously taken into account, considered the improvement of the patient's quality of life.